Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ASX listed company Phylogica has been developing a technology to administer valuable drugs through your eyes’ retinas
  • Today, the company has announced pre-clinical success in administering the technology to human cells after checking boxes on animal cell-testing just two weeks ago
  • Scientists at Phylogica argue the method of administering drugs through a patient’s eyes allows for better retention of the treatment, helping to combat cancer cells and blinding diseases
  • When testing on animal cells, the company hit a 400 per cent increase from the industry standard with its technology – today’s human cell testing showed a 92 per cent increase from the control group

Pharmaceutical company Phylogica peaked at a 25 per cent high in the ASX this morning, after the company announced a cell-breakthrough in human studies.

The company has been developing methods to deliver drugs through the eye’s retina.

Phylogica’s scientists argue this method of administering pharmaceuticals through a patient’s eyes boost the chances of combatting cancer cells and diseases that cause blindness.

Today, the company announced its ‘cell-penetrating peptide’ technology has seen a a resounding success on a trial of human cells.

This news follows just two weeks after the company reached its goal in administering the drug method to animal patients – results that showed a 400 per cent increase in efficiency from the industry standard.

In today’s trial, its administered drug method out-performed the control group’s efficiency by 92 per cent.

For Phylogica, fulfilling this success in animal and human cells accelerates the technology towards a pre-clinical data release.

The company says its next steps will be to administer the drug-delivering technology to a 3D ‘organoid’ retina model in a petri dish.

Using 3D organoid models is an emerging clinical method to mirror the complexity of a living organism with human cellular materials.

Success seen in using a 3D organoid model gives way for the increased success in an eventual human clinical trial of the technology.

Company management says it will aim to enact a pre-clinical 3D organoid retina trial by the end of this year’s final quarter. The company will then look into initiating an ‘Investigational New Drug’ study for clinical evaluation of the technology.

In today’s media release to the ASX, company management expressed gratitude towards Murdoch University, the Centre for Molecular Medicine, Innovative Therapeutics, and the Lions Eye Institute.

Share prices in PYC opened today at 3.8 cents a piece and peaked quickly to 4.40 cents from a 25 per cent gain.

Afterwards, shares trawled downwardly to an even four cents, representing a 14.3 per cent increase from this morning’s open.

The company’s market cap is currently valued for $85.5 million.

PYC by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.

" Beamtree (ASX:BMT) signs A$10.1m RippleDown contract with Ampath

Beamtree (ASX:BMT) has signed a US$7 million (A$10.1 million) five-year contract with Ampath for its RippleDown…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) accelerates international growth with first NHS contracts

Beamtree (ASX:BMT) secures its first NHS (National Health Service) contracts worth about $540,000 in combined annual…
Beamtree (ASX:BMT) - CEO, Tim Kelsey

" Beamtree (ASX:BMT) sees 91pc boost in revenue

Health data analytics company Beamtree (ASX:BMT) has reported a 91 per cent boost in group revenue…